Advanced search
Publication Cover
Clinical Ophthalmology Volume 18, 2024 - Issue
Submit an article Journal homepage
72
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Real-World Analysis of the Efficacy of Bimatoprost Sustained-Release Glaucoma Implant Where American Indians Comprise the Largest Minority Population

Steven R Sarkisian Jr1 Research & Clinical Trials, Oklahoma Eye Surgeons, Oklahoma City, OK, USACorrespondence[email protected]
View further author information
&
Evann C Mitchell2 College of Medicine, University of Oklahoma, Oklahoma City, OK, USAView further author information
Pages 917-927 | Received 02 Dec 2023, Accepted 15 Mar 2024, Published online: 23 Mar 2024

Figures & data

Table 1 Demographics and Baseline Characteristics of Eyes in the Total Population

Table 2 Demographics and Baseline Characteristics of Eyes in the Subgroup of American Indian Patients

Figure 1 Mean IOP at baseline and at 1, 6 and 12 months after implant in the overall population with baseline IOP≥21 mmHg and IOP<21 mmHg.

Note: Error bars represent a 95% confidence interval determined by t–test analysis. Statistically significant difference in post-implantation IOP from baseline determined by paired t–test analysis.
Abbreviation: IOP, intraocular pressure.
Figure 1 Mean IOP at baseline and at 1, 6 and 12 months after implant in the overall population with baseline IOP≥21 mmHg and IOP<21 mmHg.

Figure 2 Mean number of IOP-lowering medications at baseline and at 1, 6 and 12 months after implant in the overall population with baseline IOP≥21 mmHg and IOP<21 mmHg.

Note: Error bars represent a 95% confidence interval determined by t–test analysis. Statistically significant difference in the number of post-implantation medications from baseline determined by paired t–test analysis.
Abbreviation: IOP, intraocular pressure.
Figure 2 Mean number of IOP-lowering medications at baseline and at 1, 6 and 12 months after implant in the overall population with baseline IOP≥21 mmHg and IOP<21 mmHg.

Table 3 IOP and IOP-Lowering Medication Outcomes at Baseline and Each Post-Implant Time Point in the Total Population and Subgroups Differentiated by Baseline IOP of 21 mmHg

Figure 3 Mean IOP at baseline and at 1, 6 and 12 months after implant in American Indian subgroups with baseline IOP ≥21 mmHg and IOP <21 mmHg.

Note: Error bars represent 95% confidence interval determined by t–test analysis. Statistically significant difference in post-implantation IOP from baseline determined by paired t–test analysis.
Abbreviation: IOP, intraocular pressure.
Figure 3 Mean IOP at baseline and at 1, 6 and 12 months after implant in American Indian subgroups with baseline IOP ≥21 mmHg and IOP <21 mmHg.

Figure 4 Mean number of IOP-lowering medications at baseline and at 1, 6 and 12 months after implant in American Indian subgroups with baseline IOP ≥21 mmHg and IOP <21 mmHg.

Note: Error bars represent 95% confidence interval determined by t–test analysis. Statistically significant difference in the number of post-implantation medications from baseline determined by paired t–test analysis.
Abbreviation: IOP, intraocular pressure.
Figure 4 Mean number of IOP-lowering medications at baseline and at 1, 6 and 12 months after implant in American Indian subgroups with baseline IOP ≥21 mmHg and IOP <21 mmHg.

Table 4 IOP and IOP-Lowering Medication Outcomes at Baseline and Each Post-Implant Time Point in the American Indian Population and Subgroups Differentiated by Baseline IOP of 21 mmHg

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.